• Home
  • News

PHARMAQ Acquires Fish Vaccination Company Nordland Sett Vaks

Nordland Sett Vaks is a leading fish vaccination company renowned for its high quality vaccination machines and focus on innovation

• Acquisition will enable PHARMAQ to offer complete vaccination solutions

• PHARMAQ to support Nordland Sett Vaks’ international expansion

Category:

Tuesday, January 3, 2017 10:30 am EST

Dateline:

OSLO, NORWAY
"We believe PHARMAQ is the perfect partner to support our growth plans"

OSLO, NORWAY – Jan. 3, 2017 - PHARMAQ, a business of Zoetis, today announced the acquisition of the Norwegian  company Nordland Sett Vaks, an innovator in the manufacture and marketing of high quality vaccination machinery for the aquaculture industry. Nordland Sett Vaks is based in Nesna, Norway, and offers a wide range of fish vaccination services and sale of vaccination machines to fish farming companies in Norway, the UK and in the Mediterranean region. Terms of the transaction were not disclosed.

“We have known Nordland Sett Vaks for a long time, and we have been very impressed with their high focus on quality and innovative solutions. We are delighted to start working even closer together with Nordland Sett Vaks and to support the company’s international expansion,” said Morten Nordstad, President of PHARMAQ.

Nordland Sett Vaks was established in 1995, and it is today a leading machine fish vaccination company. Nordland Sett Vaks offers machine fish vaccination services and vaccination machines for a variety of different fish species in several markets.

“We believe PHARMAQ is the perfect partner to support our growth plans” said the founders of Nordland Sett Vaks, Jørn Ståle Pettersen and Remy Kristian Oddøy, who both will continue to lead the company as part of PHARMAQ.

“Nordland Sett Vaks will enable PHARMAQ to offer complete vaccination solutions to our customers all over the world, and we furthermore believe that safe and efficient vaccination services will help increase the adoption of the use of vaccines in several markets,” said Svein Alexandersen, Senior Manager Customer Service for Norway and Nordics, PHARMAQ.

About PHARMAQ
PHARMAQ is the global leader in vaccines and innovation for aquaculture and part of Zoetis, the world leader in animal health. The company provides environmentally sound, safe and efficacious health products to the global aquaculture industry through targeted research and the commitment of dedicated people. Production facilities, administration and research and development activities are based in Norway with subsidiaries in Chile, United Kingdom, Vietnam, Turkey, Spain, Panama and Hong Kong. PHARMAQ has approximately 200 employees. The company's products are marketed in Europe, North and South America, and Asia. For further information, visit the company's website at www.pharmaq.no.

About Zoetis
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2015, the company generated annual revenue of $4.8 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.

DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future guidance, future operating models, expectations regarding products, future use of cash and dividend payments, tax rate and tax regimes, changes in the tax regimes and laws in other jurisdictions, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

Media Contacts:
Morten Nordstad, President, PHARMAQ
Mobile: +47 907 52 853

Jørn Ståle Pettersen, Founder, Nordland Sett Vaks
Mobile: +47 900 71726